Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit

WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Remy Luthringer, PhD, president and chief scientific officer at Minerva, will present a review of company pipeline research in a panel discussion at the CNS Summit meeting being held at the Boca Raton Resort and Club in Boca Raton, Florida, November 13-16, 2014.

Dr. Luthringer’s presentation will take place during the CNS Summit Scientific Session being held from 9 AM to noon ET on Sunday, November 16, 2014.

About Minerva

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva’s common stock is listed on the NASDAQ Global Market where it trades under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com/.

CONTACT: Media Contact:

         David Salisbury

         Berry & Company Public Relations

         Tel: 212-253-8881

         dsalisbury@berrypr.com



         Investor Contact:

         Renee Leck

         Stern Investor Relations

         Tel: 212-362-1200

         renee@sternir.com

Source: Minerva Neurosciences, Inc

News Provided by Acquire Media